Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.

@article{Eisen2012RegorafenibFP,
  title={Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.},
  author={Tim Eisen and Heikki Joensuu and Paul Nathan and Peter G. Harper and Marek Zbigniew Wojtukiewicz and Steve Nicholson and A. K. Bahl and Piotr Tomczak and Seppo Pyrhonen and Kate M. Fife and Petri Bono and Jane Boxall and Andrea Veiga Wagner and Michael E. Jeffers and Tiffany C. Lin and David I Quinn},
  journal={The Lancet. Oncology},
  year={2012},
  volume={13 10},
  pages={1055-62}
}
BACKGROUND Regorafenib inhibits VEGF receptors 1, 2, and 3 and PDGF receptors like other anti-angiogenic tyrosine-kinase inhibitors approved for treatment of advanced renal-cell cancer. Regorafenib also inhibits other potentially important angiogenic kinases like TIE2, activation of which is thought to be important in tumour escape mechanisms. This phase 2, open-label, non-randomised study assessed the safety and efficacy of the multikinase inhibitor regorafenib for treatment of renal-cell… CONTINUE READING